Daiken Medical (7775) Fundamentals 2026 — P/E 13.4x, Revenue Analysis | SniperIQ
Daiken Medical (7775) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥12.3B, trading at ¥429.00 on the JPX. This SniperIQ fundamentals page covers Daiken Medical's valuation (P/E 13.4x, P/B 1.6x), profitability (net margin 9.0%), revenue (¥10.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Daiken Medical's market cap?
Daiken Medical (7775) has a market capitalization of approximately ¥12.3B, trading at ¥429.00 on the JPX. Market cap moves with the live share price.
What is Daiken Medical's P/E ratio?
Daiken Medical's trailing twelve-month P/E ratio is 13.4x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Daiken Medical?
Daiken Medical runs a net profit margin of 9.0%, a gross margin of 38.4%, and an operating margin of 12.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Daiken Medical generate?
Daiken Medical reported revenue of ¥10.3B for fiscal year 2025, with net income of ¥923M and earnings per share (EPS) of 32.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Daiken Medical pay a dividend?
Daiken Medical offers a trailing dividend yield of about 4.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Daiken Medical financially healthy?
Daiken Medical carries a debt-to-equity ratio of 0.29x and a current ratio of 2.58x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Daiken Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Daiken Medical (7775) the key facts are: market cap ¥12.3B, P/E 13.4x, revenue ¥10.3B, 52-week range 409-489. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Daiken Medical's full fundamentals live
Get Daiken Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.